Psoriasis

Mark Lebwohl, MD, discusses his recent presentation from AAD VMX 2021 regarding new data for various biologics for the treatment of psoriasis.

Study findings show calcipotriene-betamethasone foam to be safe and moderately effective in skin of color patients with psoriasis but failed to meet several secondary endpoints and to demonstrate statistically significant changes.

In recent phase 3 trials, deucravacitinib demonstrated progress toward becoming a potential new treatment in moderate to severe plaque psoriasis.